ALNOX.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...

Stats
今日成交量	10.21M
平均成交量	4.35M
市值	0.00
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.187
ATR14	€0 (0.00%)

NOXXON Pharma NV 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

NOXXON Pharma NV 财务报表

Annual	2021
营收:	€0.00
毛利润:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2021
营收:	€0.00
毛利润:	€0.00 (0.00 %)
EPS:	€-45.99

FY	2020
营收:	€0.00
毛利润:	€0.00 (0.00 %)
EPS:	€-32.16

FY	2019
营收:	€0.00
毛利润:	€-1.03M (0.00 %)
EPS:	€-7.72

Financial Reports:

No articles found.

NOXXON Pharma NV

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.